Abstract. Targeted gene therapy needs to be implemented for future therapies to ensure efficient activity at the site of patient primary tumors or metastases without causing intolerable sideeffects. One of the elements of gene therapy is vector, which includes viral and non-viral vector. In the present study, we constructed a novel non-viral targeted gene therapeutic system by using the new minicircle (MC) producing plasmid for Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (NPC). Molecular cloning technique was used to construct plasmids and electrophoretic analysis. Dual-luciferase reporter assay was used to evaluate the expression of luciferase. Fluorescence microscope was used to detect the expression of enhanced green fluorescence protein (EGFP). We constructed a new MC producing system pMC.BESPX-origin of plasmid replication (oriP), and demonstrated that this system could produce highly purified MC-oriP. Furthermore, our results showed that MC-oriP vector produced by the new system could mediate targeted luciferase gene expression in EBV-positive NPC cells. In addition, we verified that MC could mediate enhanced transgene expression compared with parent plasmid through EGFP transfection. The present study constructed a targeted expression vector pMC.BESPX-oriP which could carry diversified therapeutic genes for EBV-positive NPC and provides a new approach for MC-based therapies.
Introduction
One of the most important objectives of gene therapy is the development of safe and efficient systems for gene transfer in eukaryotic cells. There are 2 strategies to provide target genes for gene transfer: viral-based and non-viral-based systems (1) . Although viral-based systems have shown high transfection efficiency in vivo, they have serious disadvantages, such as immunogenicity and inflammatory response (2) . Non-viral gene delivery strategies are usually based on plasmid DNA (pDNA) carrying the gene of interest. pDNA is an attractive platform for gene delivery since it is a non-viral, non-integrating vector that is safe, inexpensive, stable and easily manipulated (3) . The popularity of pDNA continues to increase (18.3% of trials compared to 18% in 2007 and 14% in 2004) , and it is the most popular non-viral system used in clinical trials (4) . Conventional plasmid vectors include a bacterial backbone and a transcription unit. However, these sequences may cause undesirable effects such as the production of antibodies against bacterial proteins expressed from cryptic upstream eukaryotic expression signals, changes in eukaryotic gene expression caused by the antibiotic resistance marker, and immune responses to CpG sequences (5, 6) .
Compared to conventional plasmids, minicircle (MC) DNAs devoid of plasmid bacterial sequences are superior as non-viral DNA vector for multiple reasons: i) relative safety due to the reduced numbers of inflammatory unmethylated CpG motifs; ii) more efficient transgene expression due to its reduced size; and iii) more robust and persistent transgene expression (7) (8) (9) . Previous studies have demonstrated that the use of MCs may offer a promising avenue for safe and efficacious non-viral-based gene therapies (6, (10) (11) (12) .
The goal of cancer treatment is to selectively eliminate malignant cells while leaving normal tissues intact (13) . Therefore, targeted strategies need to be implemented for future therapies to ensure efficient activity at the site of patient primary tumors or metastases without causing intolerable side-effects. Nasopharyngeal carcinoma (NPC) is prevalent in South China, North Africa and among Alaskan Eskimos. A unique feature of NPC is that nearly 100% of anaplastic or poorly differentiated NPCs contain Epstein-Barr virus (EBV)
A new version of targeted minicircle producer system for EBV-positive human nasopharyngeal carcinoma (14) , which are expressed exclusively in the malignant tissues but not in the surrounding normal tissues. This difference provides an exploitable opportunity for tumor-specific targeting. Initial genetic dissections of EBV identified one viral protein, Epstein-Barr nuclear antigen 1 (EBNA1), and one region of the viral genome, termed latent origin of plasmid replication (oriP), as being necessary and sufficient for replication of the viral plasmid. Previous studies have determined that EBNA1 is essential for regulating the transcription of the transforming genes of EBV (15) (16) (17) . Additionally, EBNA-1, the only viral protein required for the replication of EBV in latently-infected cells, is found in all EBV-associated malignancies (18) . The oriP is composed of two separable cis elements, the family of repeats (Fr) and dyad symmetry element (DS) (19) . The Fr element consists of 20 tandem 30-bp repeats and acts as a transcriptional enhancer for heterologous promoters when it is bound by EBNA1. Based on these features, the oriP-CMV promoter has been exploited for targeted gene therapy in EBV-positive NPC (20) . Due to these factors, we have developed a novel MC targeted therapy system in which transgene expression is under the transcriptional regulation of the oriP-CMV promoter (hereinafter referred to as oriP promoter). The binding of EBNA1 to the Fr domain in oriP region activates the transcription of downstream genes. Selective expression of the therapeutic gene is successfully achieved in vitro and in vivo, indicating the feasibility of MC-oriP as a safe and highly effective gene therapy system for the treatment of NPC (21) .
However, the major obstacle to widespread use of MCs is their time-consuming, labor-intensive production. In previous MC production schemes, the MC producer plasmid p2ΦC31 contained a transgene expression cassette flanked with attB and attP, a set of inducible enzyme genes (a gene encoding homing endonucle ase I-SceI and two copies of the gene encoding ΦC31 integrase) and an I-SceI recognition site (9) . The attB and attP sites are the bacterial and phage attachment sites of ΦC31 integrase, and the ΦC31 and I-SceI genes are regulated by the l-arabinose-inducible araCBAD system. MC DNA is generated by recombination between the attB and attP sites, and I-SceI initiates the destruction of the pDNA backbone circle by cutting through the engineered I-SceI site. Although the yields from this protocol were ~1 mg of MC DNA from 1 liter of overnight culture, the preparations still con tained ~3-15% of the input MC producer plasmid plus the plasmid backbone circle as contaminants. In addition to CsCl equilibrium gradient centrifugation to remove these unwanted DNAs, the production procedure is four labor-intensive days longer than routine plasmid production protocols (22) .
Therefore, Chen et al presented a new system including the bacterial strain ZYCY10P3S2T plus the MC producer plasmid pMC.BESPX that allows simple, rapid and inexpensive pro duction of a high-quality form of MCs. It enabled three improvements over the previous system (9) . First, the procedure was simplified considerably and, compared to a routine plasmid preparation, required only an additional temperature change and 5-h incubation after addition of l-arabinose. Second, the yield of MC was 3.4-4.8 mg/1,000 ml of overnight culture, making it ~3-5-fold higher than the previous MC producing system. In addition, compared with the previous MC production protocol, there were 10-fold fewer contaminating pDNAs, ranging from 0.4% to 1.5% of the input MC preparation. On a molar scale, the yield of MC was 20-70% higher than the MC producer plasmid. Third, the cost of MC production was similar to that of a standard plasmid. These production improvements, along with their superior expression profiles, make it feasible for MC DNA vectors to be used in place of pDNAs in mammalian expression studies (22) .
In the present study, we developed a new targeted MC producing system by introducing targeted promoter oriP into the MC producer plasmid pMC.BESPX. Then, we demonstrated that this system could produce high-quality form of targeted MCs and the targeted MC containing oriP promoter could selectively express gene in vitro. To our knowledge, this is the first report on the new MC producer plasmid pMC. BESPX used in targeted gene expression. This system (pMC. BESPX-oriP) provides new targeted therapeutic vector for EBV-positive NPC.
Materials and methods
Construction of recombinant parent plasmids. Plasmid pMC. BESPX (4,084 bp) and bacterial strain ZYCY10P3S2T were gifts from Dr Zhiying Chen (Stanford university, Stanford, CA, uSA) (22) . Plasmid pSP72-oriP-luci-polyA was constructed by our laboratory (21) . pcDNA3.1 (5,428 bp) and the E. coli strains top 10 were purchased from Invitrogen. pGL3-control was purchased from Promega. pEGFP-C2 (4.7 kb) was obtained from Clontech.
The 1-kb CMV-multiple cloning sites (MCS)-polyA fragment was amplified by PCr from pcDNA3.1 plasmid (Fig. 1A) and subcloned into the pMC.BESPX plasmid to create intermediate plasmid pMC.BESPX-CMV-MCS-polyA (5.1 kb, Fig. 1B) . Then, parent plasmid pMC.BESPX-CMV-luci (6.7 kb, Parent plasmid pMC.BESPX-oriP-luci (6.9 kb) was constructed by inserting the 2.8-kb SalI-oriP-luciferasepolya-XhoI fragment from the intermediate plasmid pSP72-oriP-luci-polyA ( Fig. 2A) into the SalI sites of pMC. BESPX; SalI and XhoI are isocaudamers (Fig. 2B ).
Production and purification of MCs. MC-luciferase (2.8-kb MC-oriP-luci and 2.6-kb control MC-CMV-luci) were produced according to the methods described by Chen et al (22) . Our present MC producing system, the strain ZYCY10P3S2T plus the MC producer plasmid pMC.BESPX-oriP-luci and pMC.BESPX-CMV-luci, allowed for a greatly simplified MC production protocol (Fig. 3A) . On the morning of day 1, we inoculated cells from one transformed colony in 2 ml of TB (pH 7.0) with Kan (50 µg/ml) and incubated at 37˚C with shaking at 250 rpm. Later that day, we amplified the bacteria by combining 25 µl of culture to every 100 ml TB containing Kan (50 µg/ml) and continued incubation overnight. At the end of the culture period, the OD600 was 4-5 with a pH of ~6.5. On day 2, we prepared an MC induction mix comprising 100 ml fresh LB, 4 ml 1N sodium hydroxide and 0.1 ml 20% L-arabinose and combined it with a 100 ml overnight culture, and incubated the culture at 32˚C with shaking at 250 rpm for an additional 5 h. We used Qiagen plasmid purification kits to isolate MC from bacterial lysates following the manufacturer's protocol (22) .
Cells and culture conditions. The cell lines used in the present study were 293 (human embryonic kidney cell line, EBV-negative), NP69 (immortalized human nasopharyngeal epithelial cell line, EBV-negative), 5-8F (highly metastasized NPC cell line, EBV-negative), and C666-1 (undifferentiated and the only available EBV-positive NPC cell line) (23-25). 5-8F and C666-1 cells were maintained in rPMI-1640 containing 100 u/ml penicillin, 100 mg/ml streptomycin and 10% fetal bovine serum (Gibco, Paisley, Scotland) at 37˚C in a 5% CO 2 humidified atmosphere. NP69 cells were maintained in Keratinocyte-SFM (cat. 10724; Gibco, Invitrogen), and the experiments were conducted when the cells were in an exponential growth phase. C666-1 was a gift from Dr Saiwah Tsao (university of Hong Kong, Hong Kong, China). NP69 and 5-8F were kindly provided by Professor Musheng Zeng (State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen university, Guangzhou, China). The 293 cell line was maintained by our laboratory (21) .
Quantitative assay of luciferase expression mediated by targeted or control promoter.
To evaluate luciferase gene expression from MC-oriP-luci or MC-CMV-luci in EBV-negative and -positive cells, luciferase activity was measured using the Dual-Luciferase reporter assay system (Promega). Cells were seeded in 24-well culture plates the day before transfection. After one doubling, cells were cotransfected with different luciferase expressing plasmid and pGL4.73 (Promega) simultaneously at a ratio of 50:1. Cell lysates were analyzed for luciferase activity using the DualLuciferase reporter assay system and a Luminometer (Centro LB-960; Berthold Technologies) according to the manufacturers' protocols (21) .
Fluorescence detection of egfp expression mediated by parent plasmid or MC plasmid.
To further validate that MC mediated more efficient transgene expression compared with routine plasmid, we also constructed MC producer plasmid pMC.BESPX-CMV-EGFP, and isolated MC plasmid MC-CMV-EGFP. Transfections were conducted according to the manufacturer's instructions (Invitrogen). Twenty-four hours after transfection, fluorescence images of transfected 5-8F and C666-1 cells were captured using the Olympus IX71 motorized inverted microscope using FITC filter at x10 magnification (26) .
Statistical analysis. All results were evaluated using Student's t-test with SPSS 17.0 software (SSPS, Inc., Chicago, IL, uSA). p<0.05 was considered to indicate a statistically significant difference. representative results from three independent experiments are shown, and the data are presented as means ± SD.
Results

Analysis of molecular weight and purity of MCs by gel electrophoresis.
MC DNA produced by using designated protocols was purified using Qiagen plasmid purification kits and analyzed by gel electrophoresis (Fig. 3B) . Prior to electropho- resis, DNAs were digested with restriction enzyme SalI. As shown in Fig. 3 , the size of MCs was close to their expression cassette (oriP-luciferase-polyA and CMV-luciferase-polyA). Notably, there was no contaminating pDNA by macroscopic observation. This is consistent with a previous report (22) .
Selective expression of luciferase in EBV-positive C666-1 cells mediated by oriP-vectors.
To determine the transgene expression provided by the novel EBNA1-regulated MC vectors in EBV-negative cells (293, NP69 and 5-8F cells), and the only available EBV-positive NPC cell line (C666-1), the MC-luci was compared with its parent plasmid pMC.BESPX-luci. All these plasmids contained a luciferase expression cassette driven by an oriP promoter or cytomegalovirus promoter (Fig. 4) . Luciferase activity was assessed 48 h (72 h for C666-1 due to its low growth rate) after transfection using the DualLuciferase reporter assay system. Luciferase activities were 10-20-fold lower when driven by oriP promoter than by CMV promoter in EBV-negative cells (p<0.001; Fig. 4) . In contrast, luciferase activity was higher when driven by oriP promoter than by CMV promoter in the EBV-positive C666-1 cells (p<0.05; Fig. 4) . Occasionally, low levels of luciferase activity were detected in some EBV-negative cells when driven by the oriP promoter, which suggested the basal expression induced by the minimal CMV IE promoter included in oriP promoter. This observation is consistent with a previous study (20) . The expression levels of the MC groups were significantly higher than those of the corresponding parent groups, demonstrating that the MC is more efficient in mediating transgene expression in vitro (p<0.01; Fig. 4 ). 
Enhanced expression of MC-encoded egfp gene compared with parent plasmid in vitro.
The transfection efficiency of parent plasmid and MC were compared in 5-8F (Fig. 5A ) and C666-1 (Fig. 5B ) cells using Lipofectamine 2000 (Invitrogen). Twenty-four hours after transfection, there was a significant increase in GFP expression in the MC-transfected cell population compared with the parent plasmid-transfected cell population (Fig. 5) .
Discussion
Our data indicate the novel minicircle (MC) producing system pMC.BESPX-oriP could produce high-quality form of MC-oriP. Targeted and increased gene expression is successfully achieved in MC-oriP-transfected EBV-positive cells. More efficient transgene expression is reconfirmed in MC-EGFP compared with pMC.BESPX-EGFP. The novelty of the present study lies in the introduction of oriP promoter into the new MC producing system pMC.BESPX and application of this system in gene expression in EBV-positive nasopharyngeal carcinoma (NPC).
Gene therapy is an emerging field in medical and pharmaceutical sciences due to its potential to treat chronic diseases such as cancer, viral infections, myocardial infarctions and genetic disorders. Application of gene therapy is limited due to lack of suitable methods for proper introduction of genes into cells and, therefore, this is an area of interest for most researchers. To achieve successful gene therapy, development of proper gene delivery systems may be one of the most important factors. Several non-viral and viral gene transfer methods have been developed. Although the viral agents have a high transferring efficiency, they are difficult to handle due to their toxicity. To overcome the safety problems of the viral counterpart, several non-viral in vitro and in vivo gene delivery systems have been developed (27) . Plasmid DNA (pDNA) is the most popular non-viral system used in clinical trials (4) .
Standard pDNA has two components: the bacterial backbone required for plasmid propagation in bacteria and the transcription cassette for expression in mammalian cells. An MC episomal DNA vector is a circular expression cassette devoid of the bacterial pDNA backbone. pDNA size is inversely related to transfection efficiency and correspondingly, the transfection efficiency and expression levels of MC are higher than pDNA levels (12) . MCs have been used for years in preclinical gene transfer research due to their 10-1,000-fold enhancement compared with regular plasmids in long-term transgene expression in quiescent tissues in vivo and in vitro (22) . Owing to this advantage, Huang et al created MC carrying HIF-1α (MC-HIF-1α) therapeutic gene for treatment of myocardial infarction. They also demonstrated that MC could significantly improve transfection efficiency, duration of transgene expression and cardiac contractility (6). Jia et al used a single MC vector to generate transgene-free induced pluripotent stem cells (iPSCs) from adult human adipose stem cells (10). Gao et al developed a magnetic resonance imaging (MrI) visible nanoparticle to monitor MC DNA gene delivery and explore the potential of gene therapy in vivo (28) . Dietz et al also demonstrated that MC DNA is superior to pDNA in eliciting antigen-specific CD8 + T-cell responses (12).
In our previous study, we generated a safe and highly effective gene therapy system for NPC by using the MC producer plasmid p2ΦC31, which was provided by Dr Zhiying Chen (Stanford university) (21) . The MC preparations contained ~3-15% of the input MC producer plasmid plus the plasmid backbone circle as contaminants. A new system pMC.BESPX and the bacterial strain ZYCY10P3S2T that allow simple, rapid and inexpensive pro duction of a high-quality form of MCs has been presented (22) .
In the present study, we constructed a targeted MC producing system by using the novel parent plasmid pMC.BESPX and the bacterial strain ZYCY10P3S2T. We isolated MCs without macroscopic plasmid contamination (Fig. 3B) . Our results verified the superiority of pMC.BESPX in MC preparation, and is consistent with other reports (12, 22) . Then, we detected the targeted gene expression of pMC.BESPX-oriP and MC-oriP in EBV-negative and EBV-positive cells. Both in parent plasmid and in MC group, oriP promoter could mediate selective gene expression compared to CMV promoter (Fig. 4) . This indicates that MC-oriP which is produced by the new producing system constructed in the present study, could also mediate targeted gene expression. It is similar to our previous study (21) . Finally, we verified that MC was more efficient in gene expression compared with parent plasmid (Fig. 5) . Our results suggest that pMC.BESPX-oriP could carry various therapeutic gene and produce high-quality MC which can be used in targeted gene therapy for EBV-positive NPC.
In conclusion, we showed for the first time the application of targeted promoter oriP in the novel MC producing plasmid pMC.BESPX, and demonstrated the selective expression of pMC.BESPX-oriP, as well as its inducing product MC-oriP. We constructed a targeted expression vector which could carry diversified therapeutic gene for EBV-positive NPC. The present study provides a new approach toward MC-based therapies.
